AIOCD Pharmasofttech AWACS report points out that the Indian Pharmaceutical Market (IPM) has posted growth of 7.7 per cent during May 2016 at Rs. 8,449 crore. Indian companies posted growth of 7.9 per cent and MNCs 7 per cent. Mankind grew at 18.7 per cent, Abbott by 11.4 per cent and Alkem by 10.6 per cent. Out of 50 top companies, 18 corporates have crossed the growth of IPM for the month of May 2016. Bharat Serum has the highest growth of 42.8 per cent followed by Wallace at 29.5 per cent and Eris at 24.4 per cent. Amongst the top 50 in MNCs, Janssen grew at 18 per cent followed by Abbott at 11.4 per cent and Novartis at 9.5 per cent.

The NLEM 2013 containing molecules market grew at 2.6 per cent whereas the non DPCO market grew by 8.6 per cent resulting in an overall growth of 7.7 per cent for May 2016. NLEM and non-NLEM category showed unit growth of 0.8 per cent and negative 3.1 per cent respectively.

From therapy perspective 14 therapies have outgrown the IPM growth. Respiratory market grew at 0.6 per cent, gastrointestinal market grew at 5.9 per cent, pain and analgesics market grew at 5.1 per cent whereas anti-infectives grew at 2.7 per cent. Anti-diabetic market grows at 14.9 per cent and cardiac at 10.2 per cent, neuro/CNS at 10.3 per cent in chronic business. Anti-malarials grew at negative 13.2 per cent, VMS market at 9.8 per cent. Derma market improved by 8.6 per cent and Urology market at 11.3 per cent.

From regional perspective 15 regions have outgrown the IPM growth. Odisha market grew the highest at 14.2 per cent followed by Mumbai city market at 13.8 per cent and Karnataka market at 13.5 per cent.

Amoxycillin plus clavulanic acid market registered growth of 2.8 per cent and glimepiride plus metformin market grew at 20.2 per cent. The markets of paracetamol grew at 14 per cent, atorvastatin declined by 1 per cent, probiotic microbes improved by 17.1 per cent and babcillus clausii market by 27.2 per cent.

Total 360 brands and 608 SKUs launched in May 2016. Top 3 new brands for May were Sofocure, Ppppanderm NM, Cabtana. Sanofi launches Lixisenatide – Lyxumia and Novartis launches Ruxolitinib – Jakavi. Biggest new launch by a MNC is Mydecla from Mylan in May 2016. Mixtard leads the pack with Rs. 37 crore followed by Glycomet GP at Rs. 31 crore, Lantus at Rs. 27 crore and Galvus met at Rs. 25 crore.